The most robust data on anti-tumour activity and efficacy have been generated from trials using pan-FGFR inhibitors—specifically, trials in urothelial cancers with FGFR3 mutations and iCCA with FGFR2 fusions, as described below. This evidence concerns the gene FGFR3 and neoplasm.